SCA
PPCB

Sassicaia Capital Advisers’s Propanc Biopharma PPCB Stock Holding History

Sassicaia Capital Advisers’s Portfolio PPCB Stock Details PPCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.7K Buy
+640
New +$3.8K ﹤0.01% 33

Other funds holding PPCB

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Sassicaia Capital Advisers's PPCB Position: Q1 2026 in Review

Sassicaia Capital Advisers opened a new position in Propanc Biopharma (PPCB) in Q1 2026: 640 shares worth $1.7K. The stake represents ﹤0.01% of the portfolio and ranks #33 among its holdings.

6 funds tracked by Wall St. Rank hold PPCB as of Q1 2026.

  • Sassicaia Capital Advisers held 640 shares of Propanc Biopharma worth $1.7K as of Q1 2026.
  • Propanc Biopharma was a new Sassicaia Capital Advisers position in Q1 2026.
  • Propanc Biopharma made up ﹤0.01% of Sassicaia Capital Advisers's portfolio in Q1 2026, its #33 holding.
  • 6 funds tracked by Wall St. Rank held Propanc Biopharma as of Q1 2026.

Based on Sassicaia Capital Advisers's 13F filing for Q1 2026, filed 13 May 2026.